retatrutide addiction and the Grey Market: Buyer Beware – Sarah Hormachea Exploring Retatrutide: Risks and Research
Description
You're held accountable by group members
The "52-week window" refers to the timeframe of the Hansen et al
Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor agonist, hitting two incretin receptors instead of one, which explains its superior weight loss outcomes in clinical trials
Chronic Conditions: Risks for kidney disease, infections, and clotting disorders also fell significantly
Y., Yang J
All other data are available from the corresponding author upon reasonable request
